Phase II study of neoadjuvant paclitaxel and cisplatin for operable and locally advanced breast cancer: analysis of 126 patients.
about
Current approaches in treatment of triple-negative breast cancerTriple-negative breast cancer: role of specific chemotherapy agentsTBCRC 008: early change in 18F-FDG uptake on PET predicts response to preoperative systemic therapy in human epidermal growth factor receptor 2-negative primary operable breast cancer.Effectiveness of an Adjuvant Chemotherapy Regimen for Early-Stage Breast Cancer: A Systematic Review and Network Meta-analysis.Influence of dosing times on cisplatin-induced peripheral neuropathy in rats.Sentinel lymph node biopsy does not apply to all axillary lymph node-positive breast cancer patients after neoadjuvant chemotherapyWeekly cisplatin, epirubicin, and paclitaxel with granulocyte colony-stimulating factor support vs triweekly epirubicin and paclitaxel in locally advanced breast cancer: final analysis of a sicog phase III study.Preoperative concurrent paclitaxel-radiation in locally advanced breast cancer: pathologic response correlates with five-year overall survival.A phase II study of neoadjuvant chemotherapy with docetaxel, cisplatin and trastuzumab for T2 breast cancers.Preoperative weekly cisplatin, epirubicin, and paclitaxel (PET) improves prognosis in locally advanced breast cancer patients: an update of the Southern Italy Cooperative Oncology Group (SICOG) randomised trial 9908.A multicenter prospective phase II trial of neoadjuvant epirubicin, cyclophosphamide, and 5-fluorouracil (FEC100) followed by cisplatin-docetaxel with or without trastuzumab in locally advanced breast cancer.Cisplatin versus carboplatin in combination with paclitaxel as neoadjuvant regimen for triple negative breast cancer.
P2860
Q26801549-537FFCEB-D5E5-4CBA-B972-DF5858AC8DEBQ33900930-BDA10621-6E7B-497D-9A50-36532A35886AQ35155635-BEB1F0CA-DEF9-4482-A5C4-D438252D45E8Q35786472-FCB58F5D-81D2-410F-9F9C-82ADFCFEDFF6Q36146524-3D399E6B-1E99-488D-8B35-55477E3BB2CBQ36439409-89748822-2813-4E41-B08B-F1023B4FAC14Q36612439-9930E770-2BEF-4592-B4B4-D0C75F5EBEDAQ36848102-49194372-AE86-4566-BA91-76C7EC87D6E3Q42637089-2F4F3FD9-9A2B-450B-A860-A84A821CFEC5Q43264870-1CAF0E4E-159D-4DFD-9A5F-794926F82F95Q46435201-7DDABBD7-6CB8-43F2-8317-662DB46EE911Q47101500-68AD2A59-A1A1-4F89-A75E-41B6C5492739
P2860
Phase II study of neoadjuvant paclitaxel and cisplatin for operable and locally advanced breast cancer: analysis of 126 patients.
description
2004 nî lūn-bûn
@nan
2004年の論文
@ja
2004年論文
@yue
2004年論文
@zh-hant
2004年論文
@zh-hk
2004年論文
@zh-mo
2004年論文
@zh-tw
2004年论文
@wuu
2004年论文
@zh
2004年论文
@zh-cn
name
Phase II study of neoadjuvant ...... cer: analysis of 126 patients.
@ast
Phase II study of neoadjuvant ...... cer: analysis of 126 patients.
@en
type
label
Phase II study of neoadjuvant ...... cer: analysis of 126 patients.
@ast
Phase II study of neoadjuvant ...... cer: analysis of 126 patients.
@en
prefLabel
Phase II study of neoadjuvant ...... cer: analysis of 126 patients.
@ast
Phase II study of neoadjuvant ...... cer: analysis of 126 patients.
@en
P2093
P2860
P356
P1476
Phase II study of neoadjuvant ...... cer: analysis of 126 patients.
@en
P2093
A M Tulbah
D S Ajarim
E M Ibrahim
M Al-Shabanah
O A Al-Malik
P2860
P2888
P304
P356
10.1038/SJ.BJC.6601616
P407
P577
2004-03-01T00:00:00Z